Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726 is registered in ClinicalTrials.gov with C4 Therapeutics, Inc. as lead sponsor.

NCT NCT04756726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04756726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Lead sponsor
C4 Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 27, 2021
Completion date
December 31, 2026
Enrollment
224 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin's, multiple myeloma